Targeting p130Cas- and microtubule-dependent MYC regulation sensitizes pancreatic cancer to ERK MAPK inhibition

To identify therapeutic targets for KRAS mutant pancreatic cancer, we conduct a druggable genome small interfering RNA (siRNA) screen and determine that suppression of BCAR1 sensitizes pancreatic cancer cells to ERK inhibition. Integrative analysis of genome-scale CRISPR-Cas9 screens also identify B...

Descripción completa

Detalles Bibliográficos
Autores principales: Waters, Andrew M., Khatib, Tala O., Papke, Bjoern, Goodwin, Craig M., Hobbs, G. Aaron, Diehl, J. Nathaniel, Yang, Runying, Edwards, A. Cole, Walsh, Katherine H., Sulahian, Rita, McFarland, James M., Kapner, Kevin S., Gilbert, Thomas S.K., Stalnecker, Clint A., Javaid, Sehrish, Barkovskaya, Anna, Grover, Kajal R., Hibshman, Priya S., Blake, Devon R., Schaefer, Antje, Nowak, Katherine M., Klomp, Jennifer E., Hayes, Tikvah K., Kassner, Michelle, Tang, Nanyun, Tanaseichuk, Olga, Chen, Kaisheng, Zhou, Yingyao, Kalkat, Manpreet, Herring, Laura E., Graves, Lee M., Penn, Linda Z., Yin, Hongwei H., Aguirre, Andrew J., Hahn, William C., Cox, Adrienne D., Der, Channing J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8340308/
https://www.ncbi.nlm.nih.gov/pubmed/34192548
http://dx.doi.org/10.1016/j.celrep.2021.109291

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8340308/
https://www.ncbi.nlm.nih.gov/pubmed/34192548
http://dx.doi.org/10.1016/j.celrep.2021.109291

Ejemplares similares